🚀 VC round data is live in beta, check it out!
4basebio Valuation Multiples
Discover revenue and EBITDA valuation multiples for 4basebio and similar public comparables like Pacific Edge, Alpha Teknova, ArcticZymes, SDI Group and more.
4basebio Overview
About 4basebio
4basebio PLC is a life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for effectively and safely delivering these DNA-based products to patients. The company operates across three geographic segments: Europe, the United States, and the Rest of the World, with the majority of its revenue generated from the United States.
Founded
2019
HQ
Employees
110
Website
Financials (FY)
EV
$94M
4basebio Financials
4basebio reported last fiscal year revenue of $1M and negative EBITDA of ($15M).
In the same fiscal year, 4basebio generated $840K in gross profit, ($15M) in EBITDA losses, and had net loss of ($16M).
4basebio P&L
In the most recent fiscal year, 4basebio reported revenue of $1M and EBITDA of ($15M).
4basebio expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $1M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $840K | XXX | XXX | XXX |
| Gross Margin | — | XXX | 68% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($15M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (1176%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (1371%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($16M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (1322%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
4basebio Stock Performance
4basebio has current market cap of $120M, and enterprise value of $94M.
Market Cap Evolution
4basebio's stock price is $7.74.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $94M | $120M | 0.0% | XXX | XXX | XXX | $-1.06 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free Trial4basebio Valuation Multiples
4basebio trades at 75.5x EV/Revenue multiple, and (6.4x) EV/EBITDA.
4basebio Financial Valuation Multiples
As of March 24, 2026, 4basebio has market cap of $120M and EV of $94M.
Equity research analysts estimate 4basebio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
4basebio has a P/E ratio of (7.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $120M | XXX | $120M | XXX | XXX | XXX |
| EV (current) | $94M | XXX | $94M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 75.5x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (6.4x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (5.5x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 111.8x | XXX | XXX | XXX |
| P/E | — | XXX | (7.3x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (5.7x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified 4basebio Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
4basebio Margins & Growth Rates
4basebio's revenue in the last fiscal year grew by 84%.
4basebio Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 84% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (1176%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 49% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 38% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 151% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 502% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 1439% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
4basebio Public Comps
See public comps and valuation multiples for other Life Sciences Tools comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Pacific Edge | XXX | XXX | XXX | XXX | XXX | XXX |
| Alpha Teknova | XXX | XXX | XXX | XXX | XXX | XXX |
| ArcticZymes | XXX | XXX | XXX | XXX | XXX | XXX |
| SDI Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Bioventix | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
4basebio M&A Activity
4basebio acquired XXX companies to date.
Last acquisition by 4basebio was on XXXXXXXX, XXXXX. 4basebio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by 4basebio
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free Trial4basebio Investment Activity
4basebio invested in XXX companies to date.
4basebio made its latest investment on XXXXXXXX, XXXXX. 4basebio invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by 4basebio
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout 4basebio
| When was 4basebio founded? | 4basebio was founded in 2019. |
| Where is 4basebio headquartered? | 4basebio is headquartered in United Kingdom. |
| How many employees does 4basebio have? | As of today, 4basebio has over 110 employees. |
| Who is the CEO of 4basebio? | 4basebio's CEO is Amy Jo Walker. |
| Is 4basebio publicly listed? | Yes, 4basebio is a public company listed on London Stock Exchange. |
| What is the stock symbol of 4basebio? | 4basebio trades under 4BB ticker. |
| When did 4basebio go public? | 4basebio went public in 2021. |
| Who are competitors of 4basebio? | 4basebio main competitors are Pacific Edge, Alpha Teknova, ArcticZymes, SDI Group. |
| What is the current market cap of 4basebio? | 4basebio's current market cap is $120M. |
| What is the current revenue of 4basebio? | 4basebio's last fiscal year revenue is $1M. |
| What is the current EV/Revenue multiple of 4basebio? | Current revenue multiple of 4basebio is 75.5x. |
| Is 4basebio profitable? | No, 4basebio is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.